Cardiac Output in Preeclamptic (Coload)

M

Mansoura University

Status

Enrolling

Conditions

Echocardiography

Treatments

Drug: 1000 mL of ringer's acetate solution
Drug: 250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)

Study type

Interventional

Funder types

Other

Identifiers

NCT05435573
ECHO

Details and patient eligibility

About

There is high incidence of hypertensive disorders during pregnancy.The maternal cardiovascular system had significant changes during pregnancy. The colloid oncotic pressure is decreased during preeclampsia.

Full description

Transthoracic echocardiography considered an accurate non-invasive device and has validity for measuring cardiac functions in pregnancy.

Enrollment

34 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Pre-eclampsia
  • Age 18-45 years.
  • Singleton pregnancy scheduled for elective CS delivery under spinal anesthesia.
  • American Society of Anesthesiologists (ASA Ⅱ, Ⅲ).

Exclusion criteria

  • Body mass index < 18 or ≥40 kg/m²
  • Women presenting in labor
  • Current administration of vasoactive drugs including salbutamol and thyroxin.
  • Diabetes mellitus.
  • Hemoglobin <10 g/dl.
  • Cardiovascular, cerebrovascular, or renal disease
  • Increased serum creatinine level ≥1.1 mg/dL.
  • Contraindications to spinal anesthesia:(increased intracranial pressure, coagulopathy, or local skin infection)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

34 participants in 2 patient groups

Crystalloid group
Active Comparator group
Description:
The patients will receive 1000 mL of ringer's acetate solution (250 mL over 5 minutes starting immediately after intrathecal injection using a pressurizer then 500 mL over 55 minutes then 250 mL over 60 minutes).
Treatment:
Drug: 1000 mL of ringer's acetate solution
Crystalloid-colloid group
Active Comparator group
Description:
Patients will receive 250 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride starting immediately after intrathecal injection then 500 mL of ringer's acetate solution then 250 mL of hydroxyethyl starch
Treatment:
Drug: 250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems